TELA Company Profile and Key Details

TELA has shown weak momentum, losing -12.01% over the past week and -39.04% over the past quarter, though year-to-date performance is down -20.96%. Short-term trend indicators are bullishly aligned (SMA20 -1.18%, SMA50 -16.23%, SMA200 -41.97%). The stock’s 14-day RSI is 44.06 (neutral), while the ATR of 0.1 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -69.59% below its high and over 22.61% above its low. Average 10-day trading volume of 221.01 thousand shares is slightly above the 3-month average of 173.63 thousand, indicating heightened recent market interest.

TELA Bio, Inc. (NASDAQ:TELA) closed at $0.91 USD, losing -$0.08 (-8.59%) from the previous close of $0.99. The stock is currently mid-range between its 52-week high and low $0.50 and $2.20. With a market capitalization of about $40.51 million, TELA Bio, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.30). Key stats such as the average daily volume over the past year has been around 182.12 thousand shares, in line with its 52-week average. Headquartered in Malvern, PA, TELA Bio, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Antony Koblish, the company employs approximately 209 people and listed since November 08, 2019. TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy.

TELA Bio, Inc. trades at a P/E ratio of -1.26, slightly below the S&P 500 average, with a price-to-sales ratio of 0.49 and a price-to-book ratio of -9.69 indicating negative book value, which may reflect financial stress. The P/FCF stands at -1.3, also above market averages.

TELA Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.91. This means the shares are trading below this model’s fair value.

TELA Bio, Inc. generated EPS of -$0.89 over the past year. Five-year average earnings growth is 12.91%. Wall Street analysts project EPS growth of 35.31% annually over the next five years. The latest quarter delivered EPS of -$0.21. The next quarter is forecast at -$0.18. Next year's EPS is expected at $20.75. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 4 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $6.00 to $1.00. The high target offers 559.34% upside. The low target suggests 9.89% downside. The mean target is $3.03. This offers 232.97% upside. TELA Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by 50.0%. The prior quarter beat by -11.11%. Over the last six quarters, Apple has recorded several small beats. These include -4.17% in March 20, 2025.

TELA Bio, Inc. has 39.62 million shares outstanding. The public float is 18.42 million shares, elevated short interest at 1.47% of float. This equals 460.50 thousand shares. The short ratio is 5.85 days. Institutional investors hold 77.02% of the float. Insiders own 8.42%. EW HEALTHCARE PARTNERS FUND 2, L.P. holds 7.71 million shares, EW Healthcare Partners Fund 2-UGP, LLC has 4.11 million shares and ORBIMED ADVISORS LLC has 2.41 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Our AI price prediction model suggests that TELA Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 18.23%, with price expected at $1.07 by May 29, 2026, within a range of $0.93 to $1.21 3-Month Outlook: Projected rise of 357.46%, reaching $4.14 by August 13, 2026, with a range of $3.74 to $4.42. 1-Year Outlook: Projected loss of -25.97%, with price at $0.67 by May 14, 2027, within a range of $0.00 to $0.00.

TELA Bio, Inc. (NASDAQ:TELA) shares are down -20.96% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows TELA Bio, Inc. trading at a premium to the broader market with a P/E of -1.26. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $8.56, suggesting 845.86% upside. Our AI forecast model points to short-term strength (18.23% over two weeks), a medium-term rise (357.46% over three months), and a longer-term loss (-25.97% over one year), with expected trading ranges indicating moderate volatility.